EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

8. Should clinics accept semaglutide salts or research-use-only peptides?

Dose Diligence research deskSection 01 · Page 8 of 34Last updated 17 Nov 2026

Do not approve those products as routine patient-care procurement alternatives. FDA states that semaglutide sodium and acetate are different active ingredients from those in approved medicines and that it is unaware of a lawful basis for their use in compounding. FDA also warns against products falsely marketed for research while being sold for human use. (fda.gov)

Use a product-identity stop screen:

  • Is the exact active ingredient disclosed?
  • Is the proposed product approved or compounded?
  • Is a laboratory or research designation being used to explain patient supply?
  • Does the proposal identify the actual dispensing pharmacy?
  • Can the supplier connect the product to legitimate sourcing and handling records?

Escalate identity mismatches immediately. A purity claim, test report or attractive price is not a substitute for an eligible patient-care route.

The appropriate procurement response to an unresolved identity issue is to stop onboarding—not to negotiate additional indemnity and proceed.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Section sources →